Endoscopic Duodenal Resurfacing Offers Breakthrough for Sustaining Weight Loss After Discontinuing GLP-1 Medications

REMAIN-1 trial shows duodenal mucosal resurfacing helps patients maintain weight loss after stopping tirzepatide by resetting gut metabolism.

By: AXL Media

Published: Apr 23, 2026, 6:46 AM EDT

Source: Information for this report was sourced from EurekAlert!

Addressing the Weight Rebound Challenge in GLP-1 Therapy

As the popularity of glucagon-like peptide-1 (GLP-1) medications grows, medical professionals are grappling with a significant clinical hurdle: the rapid return of lost weight once treatment stops. Data suggests that approximately 70% of individuals eventually discontinue these drugs, with many regaining their lost weight within 18 months. Lead author Shelby Sullivan, MD, highlights that while these medications are highly effective, the long-term dependency and associated costs remain major barriers for patients. The REMAIN-1 trial introduces an alternative strategy, focusing on maintaining metabolic benefits through a one-time intervention rather than indefinite pharmaceutical reliance.

The Mechanism of Duodenal Mucosal Resurfacing

Duodenal mucosal resurfacing is an investigational outpatient procedure that utilizes targeted thermal energy to ablate the inner lining of the duodenum. This section of the small intestine is critical for hormone production and metabolic signaling, but it can become thickened and dysfunctional due to high-fat and high-sugar diets. By removing this unhealthy tissue, the procedure stimulates the growth of a healthy mucosal layer, essentially resetting how the gut responds to food. According to Dr. Sullivan, this rejuvenation aims to synchronize the patient's metabolism with their new, lower body weight, providing a biological foundation for durable maintenance.

Midpoint Results of the REMAIN-1 Clinical Trial

The findings presented in the blinded, randomized trial involved 45 participants who had previously lost at least 15% of their body weight using tirzepatide. After discontinuing the medication, 29 patients underwent the resurfacing procedure while 16 received a sham treatment. Six months post-procedure, the results showed a clear divergence between the two groups. Those in the sham cohort regained 40% more weight than those who received the thermal ablation. Notably, the treatment group showed a dose-response relationship, where those with more tissue resurfaced maintained the highest percentage of their initial weight loss.